Acute myocardial infarction with lung cancer during treatment with gefitinib: the possibility of gefitinib-induced thrombosis.

作者: K. Yamaguchi , S. Kanazawa , Y. Kinoshita , M. Muramatsu , S. Nomura

DOI: 10.1159/000088548

关键词:

摘要: administration of gefi tinib was then started. A good response observed but with a grade 1–2 skin adverse toxicity ( table 1 , period A). Two months later she complained severe fatigue, and electrocardiography (ECG) revealed ischemic changes B). She diagnosed acute myocardial infarction. Therefore, the halted. On admission day, ECG sinus rhythm an ST elevation in leads V 1–3 T wave inversion 3–6 fi g. ). However, there were neither ndings nor abnormalities laboratory tests over next 24 h C). other hand, echocardiographic consistent diagnosis infarction left anterior descending area. After 2 weeks’ observation, restarted under continued treatment aspirin D). Following about tinib, minor lung cancer observed. An analysis platelet aggregation, stimulated by ADP or collagen before after weeks receiving performed. Both collagen-induced aggregations suppressed restart tinib. both exhibited tendency towards enhancement

参考文章(8)
Shigenori Kanazawa, Mikiko Muramatsu, Yoshimi Kinoshita, Kazuyuki Yamaguchi, Shosaku Nomura, Gefitinib Has the Potential of Activating Cell Immunity Against Malignant Cells Journal of Clinical Oncology. ,vol. 23, pp. 3865- 3866 ,(2005) , 10.1200/JCO.2005.05.148
Paolo Menè, Hanna E. Abboud, Michael J. Dunn, Regulation of human mesangial cell growth in culture by thromboxane A2 and prostacyclin Kidney International. ,vol. 38, pp. 232- 239 ,(1990) , 10.1038/KI.1990.191
Shigenori Kanazawa, Kazuyuki Yamaguchi, Yoshimi Kinoshita, Mikiko Muramatsu, Yutaka Komiyama, Shosaku Nomura, Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance. Clinical and Applied Thrombosis-Hemostasis. ,vol. 11, pp. 429- 434 ,(2005) , 10.1177/107602960501100409
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Isamu Okamoto, Kazuhiko Fujii, Mitsuhiro Matsumoto, Yasuhiro Terasaki, Nanae Kihara, Hirotsugu Kohrogi, Moritaka Suga, Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer. ,vol. 40, pp. 339- 342 ,(2003) , 10.1016/S0169-5002(03)00043-6
Fortunato Ciardiello, Francesco Paolo D'Armiento, A Raffaele Bianco, David Raben, Vincenzo Damiano, Paul Bunn, Cataldo Bianco, Davide Melisi, Roberto Bianco, Giampaolo Tortora, Luca Cionini, Chiara Mignogna, Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model Molecular Cancer Therapeutics. ,vol. 3, pp. 977- 983 ,(2004)
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert Smit, Steven Averbuch, Angela Macleod, Andrea Feyereislova, Rui-Ping Dong, José Baselga, None, Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 21, pp. 2237- 2246 ,(2003) , 10.1200/JCO.2003.10.038
Federico Cappuzzo, Vanesa Gregorc, Elisa Rossi, Alessandra Cancellieri, Elisabetta Magrini, Carlo Terenzio Paties, Giovanni Ceresoli, Laura Lombardo, Stefania Bartolini, Cesare Calandri, Marisa De Rosa, Eugenio Villa, Lucio Crinò, Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC Journal of Clinical Oncology. ,vol. 21, pp. 2658- 2663 ,(2003) , 10.1200/JCO.2003.01.039